Top Markets
Coin of the day
Rafael Holdings, Inc. Rafael Holdings, Inc.

Rafael Holdings, Inc.

RFL
Kedudukan dalam Saham #21321
Rafael Holdings, Inc. holds strategic investments in both early-stage and... Rafael Holdings, Inc. holds strategic investments in both early-stage and clinical pharmaceutical companies, alongside a portfolio of commercial real estate assets situated in the United States and Israel. The company's business activities are structured into two primary divisions: Pharmaceuticals and Real Estate. Its Real Estate segment manages and leases a commercial office complex, which features an integrated 800-space public parking facility. The Pharmaceutical division, conversely, focuses on developing and bringing to market therapies designed to capitalize on the metabolic distinctions between healthy cells and malignant ones. The firm's flagship drug candidate is CPI-613 (devimistat), currently undergoing evaluation in numerous clinical trials, including two pivotal Phase III registrational studies for the treatment of advanced pancreatic cancer and relapsed/refractory acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.
Harga Saham
$2.15
Disegerakkan terakhir: 2026-08-21
Modal Pasaran
$110.06M
Perubahan (1 hari)
13.46%
Perubahan (1 tahun)
37.76%
Negara
US
Perdagangan Rafael Holdings, Inc. (RFL)

Kategori

Pendapatan untuk Rafael Holdings, Inc. (RFL)
Pendapatan pada 2026 TTM: 0
Menurut laporan kewangan terkini Rafael Holdings, Inc., pendapatan semasa syarikat ialah 0. Pada tahun 2026, syarikat memperoleh pendapatan sebanyak 0, sama dengan pendapatan pada tahun 2026 yang berjumlah 0. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Rafael Holdings, Inc. dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
Tidak cukup data untuk tarikh yang disediakan.
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
$1.82B -
US
- -
DE
$742.84M -
CN
- -
DE
$1.24B -
US